Zanubrutinib 80mg, 160mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 80mg, 160mg

Reference Brands: Brukinsa (USA/EU)

Category: Oncology Cancer Care

Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, thereby reducing the growth and survival of malignant B cells. It is approved for the treatment of mantle cell lymphoma, CLL/SLL, and Waldenström’s macroglobulinemia. Zanubrutinib offers high selectivity with fewer off-target effects compared to earlier BTK inhibitors.

Product Description:

Zanubrutinib is a covalent BTK inhibitor engineered for selectivity. The first-generation drug in the class also inhibits EGFR, TEC and ITK, and those off-target effects produce the atrial fibrillation, bleeding, rash and diarrhoea that cause a substantial minority of patients to stop treatment. A cleaner molecule, dosed to achieve sustained and complete BTK occupancy in lymph nodes as well as blood, delivers the same pathway blockade with fewer reasons to discontinue.

It is used for mantle cell lymphoma, chronic lymphocytic leukaemia and small lymphocytic lymphoma, Waldenstrom macroglobulinaemia, and marginal zone lymphoma. In a head-to-head comparison in chronic lymphocytic leukaemia it showed both better progression-free survival and less atrial fibrillation than ibrutinib, which is unusual — improvements in tolerability normally cost efficacy. Neutropenia, infection, bruising and bleeding still occur, and anticoagulant co-prescription requires care.

Sourcing notes. Originator product, on patent, and widely approved. Two capsule strengths allow both once-daily and twice-daily schedules, which differ by indication — specify which is intended. Treatment continues until progression, so demand per patient is long-running and predictable. Room temperature storage.